KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.

David M Smadja, Clément R Massonnaud, Aurélien Philippe, Mickael Rosa, Sophie Luneau, Antoine Rauch, Nathan Peiffer-Smadja, Amandine Gagneux-Brunon, Julien Poissy, Maxime Gruest, Alexandre Ung, Valérie Pourcher, François Raffi, Lionel Piroth, Kévin Bouiller, Hélène Esperou, Christelle Delmas, Drifa Belhadi, Alpha Diallo, Juliette Saillard, Aline Dechanet, Noémie Mercier, Axelle Dupont, François-Xavier Lescure, François Goehringer, Stéphane Jaureguiberry, François Danion, Violaine Tolsma, André Cabie, Johan Courjon, Sylvie Leroy, Joy Mootien, Bruno Mourvillier, Sébastien Gallien, Jean-Philippe Lanoix, Elisabeth Botelho-Nevers, Florent Wallet, Jean-Christophe Richard, Jean Reuter, Alexandre Gaymard, Richard Greil, Guillaume Martin-Blondel, Claire Andrejak, Yazdan Yazdanpanah, Charles Burdet, Jean-Luc Diehl, Maya Hites, Florence Ader, Sophie Susen, France Mentré, Annabelle Dupont, Discovery Study Group

Sci Rep 15(1) 14348

PMID40274842
PMCIDPMC12022249
DOI10.1038/s41598-025-95122-7
发表日期2025-04-24
入排依据:The record describes a biomarker outcome analysis within a Phase III randomized trial (DisCoVeRy trial) for COVID-19. While it is human, randomized, Phase III, and reports time-to-event outcomes (time to hospital discharge) with HR, it is not an oncology study (COVID-19, not a malignant neoplasm). Furthermore, the primary focus is on the prognostic value of a biomarker (sST2), not on the efficacy of a drug intervention, and the report is a secondary analysis of the trial's data. Therefore, it does not meet the core eligibility criteria for an oncology drug efficacy report.
摘要

摘要

We investigated whether baseline levels of biomarkers related to endotheliopathy, thromboinflammation, and fibrosis were associated with clinical outcomes in hospitalized COVID-19 patients. We analyzed the associations between baseline levels of 21 biomarkers and time to hospital discharge and change in NEWS-2 score in patients from DisCoVeRy trial. We fitted multivariate models adjusted for baseline ISARIC 4C score, disease severity, D-dimer values, and treatment regimen. Between March 22 and June 29, 2020, 603 participants were randomized; 454 had a sample collected at baseline and analyzed. The backward selection of multivariate models showed that higher baseline levels of soluble suppressor of tumorigenicity 2 (sST2) and nucleosomes were statistically associated with a lower chance of hospital discharge before day 29 (sST2: aHR 0.24, 95% CI [0.15-0.38], p < 10-9; nucleosomes: aHR 0.62, 95% CI [0.48-0.81], p < 10-3). Likewise, higher levels of baseline sST2 were statistically associated with lower changes in the NEWS-2 score between baseline and day 15 (adjusted beta 4.47, 95% CI [2.65-6.28], p < 10-5). Moreover, we evaluated sST2 involvement in a confirmation cohort (SARCODO study, 103 patients) and found that elevated baseline sST2 levels were significantly associated with lower rates of hospital discharge before day 29 and a higher model performance (AUC at day 29 of 92%) compared to models without sST2. sST2 emerged as an independent predictor of clinical outcomes in two large cohort of hospitalized COVID-19 patients, warranting further investigation to elucidate its role in disease progression and potential as a therapeutic target.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。